Irreplaceable and Inconvenient: How Formaldehyde Persists at the Heart of Hospital Infection Control

There is a particular tension that runs through modern hospital administration — the kind that surfaces in committee meetings, procurement spreadsheets, and infection control audits. Healthcare systems across the United States have spent the better part of two decades publicly committing to greener, safer chemical environments. Hazardous substance inventories are reviewed annually. Sustainability reports cite reductions in toxic compound usage. And yet, on the floors of operating suites and in the sterilization units that service them, formaldehyde remains a quiet, stubborn presence that no amount of institutional goodwill has managed to fully dislodge.

Understanding why requires moving past the headlines and into the clinical and operational realities that govern how hospitals actually function.

The Chemistry That Made Formaldehyde Indispensable

Formaldehyde's utility in healthcare settings derives from a straightforward but powerful property: it is one of the most broadly effective biocidal agents ever identified. The molecule works by cross-linking proteins and nucleic acids within microbial cells, disrupting their structural integrity in a manner that leaves virtually no pathogen category unaffected. Bacteria, fungi, viruses, and bacterial spores — including some of the most treatment-resistant organisms encountered in clinical environments — are all susceptible.

This breadth of activity is not easily replicated. Many of the alternative disinfectants and sterilants that have gained regulatory approval over the past two decades are effective against specific pathogen categories but fall short when applied to the full spectrum of organisms that hospital infection control teams must manage. Hydrogen peroxide vapor, for instance, performs well in terminal room decontamination but presents its own material compatibility constraints. Peracetic acid-based systems are effective in certain applications but require careful handling and have limited shelf stability. Glutaraldehyde, often positioned as a direct formaldehyde substitute, carries its own toxicity profile and has faced increasing regulatory scrutiny.

Formaldehyde, despite its well-documented risks, remains the standard against which these alternatives are frequently measured — and against which they do not always favorably compare.

Wound Care: A Narrower but Persistent Application

Within the specific domain of wound management, formaldehyde's role is more targeted than its broader sterilization applications but no less contested. Formaldehyde-releasing compounds have historically been used in the treatment of certain chronic wound conditions, particularly hypergranulation tissue — the excessive, raised scar tissue that can impede healing in long-term wounds. The astringent and desiccating properties of dilute formaldehyde solutions make them effective at chemically reducing this tissue in a manner that is difficult to replicate with mechanical debridement alone.

American wound care specialists have increasingly moved toward minimizing formaldehyde-containing preparations in outpatient settings, driven by occupational exposure concerns and the availability of alternative topical agents. However, in acute care and surgical contexts — particularly in facilities managing complex wounds, post-operative infections, or immunocompromised patients — the calculus remains more complicated. The margin between clinical efficacy and patient safety is narrower in these environments, and the tolerance for suboptimal outcomes is correspondingly lower.

Regulatory Complexity and the Cost of Switching

One dimension of this issue that receives insufficient attention in public discourse is the regulatory burden associated with transitioning away from formaldehyde-based protocols. In the United States, sterilization and disinfection methods used in healthcare settings are subject to oversight from multiple federal agencies, including the FDA for device sterilization and the EPA for disinfectants classified as pesticides. Obtaining regulatory clearance for a new sterilization modality or a novel disinfectant formulation is a lengthy and expensive process.

Hospitals and healthcare networks that wish to replace formaldehyde-based systems cannot simply substitute a new product and move on. They must validate that the alternative achieves equivalent sterility assurance levels, retrain staff, update protocols, and in many cases modify or replace equipment. For large health systems managing dozens of facilities, the cumulative cost of such transitions can reach into the tens of millions of dollars — a figure that competes directly with investments in patient care infrastructure, staffing, and technology.

This economic reality does not make formaldehyde's risks acceptable. It does, however, explain why institutional inertia persists even among administrators who are fully aware of the occupational health implications.

The Occupational Exposure Problem

The workers most directly affected by formaldehyde's continued presence in healthcare settings are those who encounter it daily: sterile processing technicians, surgical nurses, operating room staff, and environmental services personnel. The Occupational Safety and Health Administration (OSHA) sets a permissible exposure limit of 0.75 parts per million as an eight-hour time-weighted average, with a short-term exposure limit of two parts per million. In practice, maintaining compliance with these thresholds in busy sterilization units requires continuous monitoring, engineering controls, and personal protective equipment protocols that are not uniformly implemented across the country's roughly 6,000 hospitals.

The National Institute for Occupational Safety and Health (NIOSH) has consistently recommended exposure limits more stringent than OSHA's current standards, reflecting the weight of evidence linking formaldehyde exposure to nasal and nasopharyngeal cancers. For healthcare workers who spend years or decades in environments where formaldehyde is routinely handled, the cumulative risk is not theoretical.

This tension — between the molecule's clinical utility and its documented harm to the people who work with it — is precisely what makes the formaldehyde paradox in healthcare so difficult to resolve.

Where the Industry Is Heading

The trajectory, if measured over decades rather than years, is clearly toward reduced reliance on formaldehyde in hospital settings. Vaporized hydrogen peroxide systems have captured significant market share in terminal sterilization applications. Nitrogen dioxide-based sterilization technologies are emerging as alternatives for certain device categories. And the investment flowing into antimicrobial surface coatings and ultraviolet disinfection systems suggests that the next generation of infection control may rely less on chemical agents of any kind.

But trajectory is not arrival. The United States healthcare system is vast, fragmented, and governed by procurement cycles that span years. Smaller community hospitals, rural critical access facilities, and federally qualified health centers often lack the capital and technical infrastructure to adopt cutting-edge sterilization technologies at the pace that academic medical centers can. In these settings, formaldehyde-based methods may remain standard practice well into the next decade, not because administrators are indifferent to the risks, but because the alternatives remain out of reach.

A Molecule That Demands Honest Accounting

The formaldehyde paradox in hospital infection control is ultimately a story about institutional complexity, not scientific ignorance. The risks are known. The alternatives exist, at least partially. And the will to transition is, in many cases, genuine. What is lacking is the combination of regulatory streamlining, capital investment, and validated performance data that would allow healthcare systems to move decisively rather than incrementally.

Until that combination materializes, formaldehyde will continue to occupy its uncomfortable position in American healthcare: a molecule that everyone agrees should eventually be replaced, and that no one has yet found a fully satisfactory way to replace.